Clinical Trial

Medication Adherence in Patients With Sarcoidosis

Study acronym: MAPS
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The goal of the study is to look at the relationship between how individuals with Sarcoidosis take the sarcoidosis medicines and how it affects the disease, to evaluate any factors that may make individuals not want to take the medicines, and to develop and refine ways to help support individuals with Sarcoidosis especially when it comes to the medicines. The overall hypothesis is higher medication adherence will be associated with better clinical outcomes in sarcoidosis. The investigators will enroll 150 patients with biopsy proven pulmonary sarcoidosis for at least one year who are on any oral treatment regimen for at least six months into a 12-month longitudinal study.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08-31 -> 2027-12-01 2026-08-14
minor Completion pushed: 2026-08-31 -> 2027-12-01 2026-08-14
Trial Details
NCT Number NCT05438095
Lead Sponsor Johns Hopkins University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Medication Adherence, Sarcoidosis
Enrollment 150 participants
Start Date 2022-05-11
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-13